Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Boehringer Ingelheim

Status: Completed

Conditions: Parkinson Disease

Treatments: Drug: Pramipexole

Study type: Observational

Funder types: Industry

Identifiers

NCT02248220

248.360

Details and patient eligibility

About

Assessment of daily maintenance dose of Sifrol®, L-dopa sparing effect, effect on tremor, depression, anhedonia and tolerability

Enrollment: 657 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with advanced idiopathic Parkinson's disease for whom combined treatment with Sifrol and L-dopa was indicated

Exclusion criteria

• NA

Trial design

657 participants in 1 patient group

Parkinson's disease patients

Treatment:

Drug: Pramipexole